CA2267165C - Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis - Google Patents
Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis Download PDFInfo
- Publication number
- CA2267165C CA2267165C CA002267165A CA2267165A CA2267165C CA 2267165 C CA2267165 C CA 2267165C CA 002267165 A CA002267165 A CA 002267165A CA 2267165 A CA2267165 A CA 2267165A CA 2267165 C CA2267165 C CA 2267165C
- Authority
- CA
- Canada
- Prior art keywords
- hydroxy
- pyridone
- formula
- employed
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Pyridine Compounds (AREA)
Abstract
Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis Compounds of the formula I
Description
WO 98h 3009 1 PCT/EP97/05070 Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis Seborrheic dermatitis is understood as meaning a disorder of the scalp which differs from simple dandruff by the presence of erythema as a sign of inflammation, by the greater degree of scaling with occasional itching and burning, and by the occurrence of eczematous changes to other body sites. It can occur in the form of patches, but also more frequently affects the whole scalp and often includes, beyond the hairline, the forehead, around the neck and the ears. In severe cases, the scalp can have a secondary infection, and the changes can then exhibit a spongy consistency, vesicle and crust formation and can weep.
Seborrheic dermatitis frequently occurs even in infancy and usually remits spontaneously at an age of 8-12 months. The scalp changes consisting of erythema) scaling and occasionally vesicles and crusts in infants can regress spontaneously within a few weeks, intermittently reoccur or persist during the entire childhood. They are frequently combined with a similar process around the eyelids, nose and ears. Later, the condition usually occurs after puberty and can last for the whole life or even increase in strength. Approximately 1-3% of the population are affected by this illness.
It is known that 1-hydroxy-2-pyridones and their salts exhibit activity against normal dandruff which is characterized by a clinically noninflam-matory scaling of the scalp occurring in nearly all people (DE 22 34 009).
The most promising type of treatment of seborrheic dermatitis until now was the topical application of corticosteroid preparations, but more recently topical therapy with antimycotic substances has gained importance.
While corticosteroid preparations display their activity exclusively via an effect on the inflammatory process, the antimycotic substances such as ketoconazole are active exclusively against the yeast fungi of the strain Pityrosporum which is assumed to be the cause of seborrheic dermatitis.
The 1-hydroxy-2-pyridones according to the invention, however, combine the properties of both classes of substance in one substance and exhibit both antiinflammatory action and antimycotic activity against Pityrosporum strains.
Seborrheic dermatitis frequently occurs even in infancy and usually remits spontaneously at an age of 8-12 months. The scalp changes consisting of erythema) scaling and occasionally vesicles and crusts in infants can regress spontaneously within a few weeks, intermittently reoccur or persist during the entire childhood. They are frequently combined with a similar process around the eyelids, nose and ears. Later, the condition usually occurs after puberty and can last for the whole life or even increase in strength. Approximately 1-3% of the population are affected by this illness.
It is known that 1-hydroxy-2-pyridones and their salts exhibit activity against normal dandruff which is characterized by a clinically noninflam-matory scaling of the scalp occurring in nearly all people (DE 22 34 009).
The most promising type of treatment of seborrheic dermatitis until now was the topical application of corticosteroid preparations, but more recently topical therapy with antimycotic substances has gained importance.
While corticosteroid preparations display their activity exclusively via an effect on the inflammatory process, the antimycotic substances such as ketoconazole are active exclusively against the yeast fungi of the strain Pityrosporum which is assumed to be the cause of seborrheic dermatitis.
The 1-hydroxy-2-pyridones according to the invention, however, combine the properties of both classes of substance in one substance and exhibit both antiinflammatory action and antimycotic activity against Pityrosporum strains.
2 In comparison to ketoconazole, the substances according to the invention -even after only a short topical contact time - concentrate rapidly in the skin layers which are relevant for fungal growth and 'thus contribute to a rapid cure.
While ketoconazole is inactive in vitro against gram-positive bacteria (Kinsman et al., J. Med. Microbiol. (1983) 16) No.2, IV), the hydroxy-pyridones according to the invention exhibit activity against gram-positive and gram-negative aerobic and anaerobic bacteria (Dittmar et al., Arzneim.-Forschung, (1981 ) 31 (II), No. 8a, pp. 1317-1322). With respect to the treatment of secondarily infected cases, this is an extremely impor-tant finding.
Compared with ketoconazole, the compounds used according to the invention furthermore have very crucial advantages with respect to their processing possibilities in pharmaceutical preparations. On account of their solubility in water, alcohols and aqueous-alcoholic solutions, the pre-paration of hair lotions and transparent gel preparations is possible without problems.
The preparations according to the invention can also be employed for the treatment of Pityriasis versicolor, a superficial, noninflammatory skin fungus disorder on the trunk.
The invention therefore relates to the use of 1-hydroxy-2-pyridones of the formula I
RZ
R' R3 OH
in which R1, R2 and R3, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and R4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
While ketoconazole is inactive in vitro against gram-positive bacteria (Kinsman et al., J. Med. Microbiol. (1983) 16) No.2, IV), the hydroxy-pyridones according to the invention exhibit activity against gram-positive and gram-negative aerobic and anaerobic bacteria (Dittmar et al., Arzneim.-Forschung, (1981 ) 31 (II), No. 8a, pp. 1317-1322). With respect to the treatment of secondarily infected cases, this is an extremely impor-tant finding.
Compared with ketoconazole, the compounds used according to the invention furthermore have very crucial advantages with respect to their processing possibilities in pharmaceutical preparations. On account of their solubility in water, alcohols and aqueous-alcoholic solutions, the pre-paration of hair lotions and transparent gel preparations is possible without problems.
The preparations according to the invention can also be employed for the treatment of Pityriasis versicolor, a superficial, noninflammatory skin fungus disorder on the trunk.
The invention therefore relates to the use of 1-hydroxy-2-pyridones of the formula I
RZ
R' R3 OH
in which R1, R2 and R3, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and R4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
3 Ar.Z
i x- cx~-Y
where X is S or O, Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine) Z is a single bond or the bivalent radicals O, S, -CR2- (R = H or (C1-C4)-alkyl) or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a chain, where - if the radicals contain 2 or more oxygen and/or sulfur atoms - the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C1-C4)-alkyl groups, Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine) methoxy, (C~-C4)-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form, for the production of a pharmaceutical for the treatment of seborrheic dermatitis.
In the radicals "Z", the carbon chain members are preferably CH2 groups. If the CH2 groups are substituted by C~-C4-alkyl groups, CH3 and C2H5 are preferred substituents. Exemplary radicals "Z" are:
-O-, -S-, -CH2-, -(CH2)m- (m = 2-10), -C(CH3)2-, -CH20-, -OCH2-, -CH2S-, -SCH2-, -SCH(C2H5)-, -CH=CH-CH20-, -O-CH2-CH=CH-CH20-, -OCH2-CH20-, -OCH2-CH2CH20-, -SCH2CH2CH2S-, -SCH2CH2CH2CH20-) -SCH2CH20CH2CH20-, -SCH2CH20CH2CH20-CH2CH2S- or -S-CH2-C(CHg)2-CH2-S-.
The radical "S" is a sulfur atom, the radical "O" is an oxygen atom. The term "Ar" denotes phenyl or fused systems such as naphthyl, tetrahydro-naphthyl and indenyl, and also isolated systems as such, which are derived from biphenyl, diphenylalkanes, Biphenyl ethers and Biphenyl thioethers.
i x- cx~-Y
where X is S or O, Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine) Z is a single bond or the bivalent radicals O, S, -CR2- (R = H or (C1-C4)-alkyl) or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a chain, where - if the radicals contain 2 or more oxygen and/or sulfur atoms - the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C1-C4)-alkyl groups, Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine) methoxy, (C~-C4)-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form, for the production of a pharmaceutical for the treatment of seborrheic dermatitis.
In the radicals "Z", the carbon chain members are preferably CH2 groups. If the CH2 groups are substituted by C~-C4-alkyl groups, CH3 and C2H5 are preferred substituents. Exemplary radicals "Z" are:
-O-, -S-, -CH2-, -(CH2)m- (m = 2-10), -C(CH3)2-, -CH20-, -OCH2-, -CH2S-, -SCH2-, -SCH(C2H5)-, -CH=CH-CH20-, -O-CH2-CH=CH-CH20-, -OCH2-CH20-, -OCH2-CH2CH20-, -SCH2CH2CH2S-, -SCH2CH2CH2CH20-) -SCH2CH20CH2CH20-, -SCH2CH20CH2CH20-CH2CH2S- or -S-CH2-C(CHg)2-CH2-S-.
The radical "S" is a sulfur atom, the radical "O" is an oxygen atom. The term "Ar" denotes phenyl or fused systems such as naphthyl, tetrahydro-naphthyl and indenyl, and also isolated systems as such, which are derived from biphenyl, diphenylalkanes, Biphenyl ethers and Biphenyl thioethers.
4 In the formula I, the hydrocarbon radial R4 is an alkyl or cyclohexyl radical which can also be bonded to the pyridone ring via a methylene or ethylene group or can contain an endomethyl group. R4 can also be an aromatic radical which, however, is preferably bonded to the pyridone radical via at least one aliphatic carbon atom.
Important representatives of the class of compounds characterized by the formula I are:
6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 6-[4-(2,4-dichlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 6-(biphenyl-4-oxymethyl)-1-hydroxy-4-methyl-2-pyridone, 6-(4-benzyl-phenoxymethyl)-1-hydroxy-4-methyl-2-pyridone, 6-[4-(2,4-dichlorobenzyl-oxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 6-(4-(4-chloro-phenoxy)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-(2,4-di-chlorobenzyl)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-cinnamyloxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 1-hydroxy-4-methyl-6-[4-(4-trifluoromethylphenoxy)phenoxymethyl]-2-pyrid-one, 1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone, 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone, 1-hydroxy-4-methyl-6-n-hexyl-) -6-iso-hexyl-, -6-n-heptyl- or -6-isoheptyl-2-pyridone) 1-hydroxy-4-methyl-6-octyl-or -6-isooctyi-2-pyridone, in particular 1-hydroxy-4-methyl-6-cyclohexyl-methyl- or -6-cyclohexylethyl-2-pyridone, where the cyclohexyl radical can in each case also carry a methyl radical, 1-hydroxy-4-methyl-6-(2-bicyclo-[2,2,1 ]heptyl)-2-pyridone) 1-hydroxy-3,4-dimethyl-6-benzyl- or -6-dimethyl benzyl-2-pyridone or 1-hydroxy-4-methyl-6-([i-phenylethyl)-2-pyridone.
The term "saturated" in this case designates those radicals which contain no aliphatic multiple bonds, i.e. no ethylenic or acetylenic bonds.
The abovementioned compounds of the formula I can be employed either in free form or as salts, use in free form is preferred.
If organic bases are used, poorly volatile bases are preferably employed, for example low molecular weight alkanolamines such as ethanolamine, diethanolamine, N-ethylethanolamine, N-methyldiethanolamine, triethanol-amine, diethylaminoethanol, 2-amino-2-methyl-n-propanol, dimethylamino-propanol, 2-amino-2-methylpropanediol, triisopropanolamine. Further poorly volatile bases which may be mentioned are, for example, ethylenediamine, hexamethylenediamine, morpholine, piperidine, piperazine, cyclohexylamine, tributylamine, dodecylamine, N,N-dimethyldodecylamine, stearylamine, oleylamine, benzylamine,
Important representatives of the class of compounds characterized by the formula I are:
6-[4-(4-chlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 6-[4-(2,4-dichlorophenoxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 6-(biphenyl-4-oxymethyl)-1-hydroxy-4-methyl-2-pyridone, 6-(4-benzyl-phenoxymethyl)-1-hydroxy-4-methyl-2-pyridone, 6-[4-(2,4-dichlorobenzyl-oxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 6-(4-(4-chloro-phenoxy)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-(2,4-di-chlorobenzyl)phenoxymethyl]-1-hydroxy-3,4-dimethyl-2-pyridone, 6-[4-cinnamyloxy)phenoxymethyl]-1-hydroxy-4-methyl-2-pyridone, 1-hydroxy-4-methyl-6-[4-(4-trifluoromethylphenoxy)phenoxymethyl]-2-pyrid-one, 1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone, 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone, 1-hydroxy-4-methyl-6-n-hexyl-) -6-iso-hexyl-, -6-n-heptyl- or -6-isoheptyl-2-pyridone) 1-hydroxy-4-methyl-6-octyl-or -6-isooctyi-2-pyridone, in particular 1-hydroxy-4-methyl-6-cyclohexyl-methyl- or -6-cyclohexylethyl-2-pyridone, where the cyclohexyl radical can in each case also carry a methyl radical, 1-hydroxy-4-methyl-6-(2-bicyclo-[2,2,1 ]heptyl)-2-pyridone) 1-hydroxy-3,4-dimethyl-6-benzyl- or -6-dimethyl benzyl-2-pyridone or 1-hydroxy-4-methyl-6-([i-phenylethyl)-2-pyridone.
The term "saturated" in this case designates those radicals which contain no aliphatic multiple bonds, i.e. no ethylenic or acetylenic bonds.
The abovementioned compounds of the formula I can be employed either in free form or as salts, use in free form is preferred.
If organic bases are used, poorly volatile bases are preferably employed, for example low molecular weight alkanolamines such as ethanolamine, diethanolamine, N-ethylethanolamine, N-methyldiethanolamine, triethanol-amine, diethylaminoethanol, 2-amino-2-methyl-n-propanol, dimethylamino-propanol, 2-amino-2-methylpropanediol, triisopropanolamine. Further poorly volatile bases which may be mentioned are, for example, ethylenediamine, hexamethylenediamine, morpholine, piperidine, piperazine, cyclohexylamine, tributylamine, dodecylamine, N,N-dimethyldodecylamine, stearylamine, oleylamine, benzylamine,
5 dibenzylamine, N-ethylbenzylamine, dimethylstearylamine, N-methylmorpholine, N-methylpiperazine, 4-methylcyclohexylamirie, N-hydroxyethylmorpholine. The salts of quaternary ammonium hydroxides such as trimethylbenzylammonium hydroxide, tetramethylammonium hydroxide or tetraethylammonium hydroxide can also be used, furthermore guanidine and its derivatives, in particular its alkylation products. However, it is also possible to employ as salt-forming agents, for example, low molecular weight alkylamines such as methylamine, ethylamine or triethylamine. Suitable salts for the compounds to be employed according to the invention are also those with inorganic cations, for example alkali metal salts, in particular sodium) potassium or ammonium salts, alkaline earth metal salts such as, in particular, the magnesium or calcium salts, as well as salts with bi- or tetravalent cations, for example the zinc, aluminum or zirconium salt.
The active compounds to be employed in the preparations of the compound of the formula I can be prepared, for example, according to processes given in US 2 540 218.
For the use according to the invention of the compounds mentioned, liquid to semisolid pharmaceutical preparations, in particular hair lotions, shampoos, liquid soaps, as well as cream, ointment and gel preparations, are suitable.
In this case, these are always preparations which, depending on their actual intended use, are applied to the skin and/or to the scalp for a shorter or longer time. Due to the addition of the compounds according to the invention, an effective treatment of the seborrheic dermatitis is brought about.
If the preparations according to the invention are present as shampoo, they can be in clear liquid or opaque liquid form, in cream form or even gelatinous. The surfactants on which these shampoos are based can be of
The active compounds to be employed in the preparations of the compound of the formula I can be prepared, for example, according to processes given in US 2 540 218.
For the use according to the invention of the compounds mentioned, liquid to semisolid pharmaceutical preparations, in particular hair lotions, shampoos, liquid soaps, as well as cream, ointment and gel preparations, are suitable.
In this case, these are always preparations which, depending on their actual intended use, are applied to the skin and/or to the scalp for a shorter or longer time. Due to the addition of the compounds according to the invention, an effective treatment of the seborrheic dermatitis is brought about.
If the preparations according to the invention are present as shampoo, they can be in clear liquid or opaque liquid form, in cream form or even gelatinous. The surfactants on which these shampoos are based can be of
6 anionic, cationic, nonionic or amphoteric nature and can also be present as a combination of these substances.
Preferably, however, anionic surfactants are employed on their own or as a mixture with other anionic surfactants as base surfactants - if appropriate with addition of amphoteric surfactants as cosurfactant.
As the sole detergent substances, amphoteric surfactants are virtually insignificant, since their foaming behavior, thickenability and partly also skin and eye mucous membrane tolerability are only moderate. In combination with various anionic surfactants, however, precisely these properties are synergistically improved. This explains the relatively great importance of the amphoteric surfactants for the optimization of anionic shampoo bases.
Nonionic surfactants can also be employed as cosurfactants.
Examples of anionic detergent substances of this type which may be mentioned are: (C~ p-C2p)-alkyl- and -alkylenecarboxylates, alkyl ether carboxylates, fatty alcohol sulfates, fatty alcohol ether sulfates, alkylol-amide sulfates and sulfonates, fatty acid alkyolamide polyglycol ether sulfates, alkanesulfonates and hydroxyafkanesulfonates, olefinsulfonates, acyl esters of isothionates, a-sulfofatty acid esters, alkylbenzosulfonates, alkylphenol glycol ether sulfonates, sulfosuccinates, sulfosuccinic acid hemiesters and diesters, fatty alcohol ether phosphates, protein-fatty acid condensation products, alkylmonoglyceride sulfates and sulfonates, alkylglyceride ether sulfonates, fatty acid methyltaurides, fatty acid sarcosinates or sulforicinoleates. These compounds and their mixtures are used in the form of their water-soluble or water-dispersible salts, for example the sodium, potassium, magnesium, ammonium, mono-, di- and triethanolammonium as well as analogous alkylolammonium salts.
Examples of amphoteric surfactants which can be added to the shampoos are: N-((C~ 2-C1 g)-alkyl)-~i-aminopropionates and N-((C12-C1 g)-alkyl)-~3-iminodipropionates as alkali metal and mono-) di- and trialkylol-ammonium salts; N-acylamidoalkyl-N,N-dimethylacetobetaine, preferably N-((Cg-C~ g)-acyl)amidopropyl-N,N-dimethylacetobetaine; (C12-C1 g)-alkyl-dimethylsulfopropylbetaine; amphoteric surfactants based on imidazoline
Preferably, however, anionic surfactants are employed on their own or as a mixture with other anionic surfactants as base surfactants - if appropriate with addition of amphoteric surfactants as cosurfactant.
As the sole detergent substances, amphoteric surfactants are virtually insignificant, since their foaming behavior, thickenability and partly also skin and eye mucous membrane tolerability are only moderate. In combination with various anionic surfactants, however, precisely these properties are synergistically improved. This explains the relatively great importance of the amphoteric surfactants for the optimization of anionic shampoo bases.
Nonionic surfactants can also be employed as cosurfactants.
Examples of anionic detergent substances of this type which may be mentioned are: (C~ p-C2p)-alkyl- and -alkylenecarboxylates, alkyl ether carboxylates, fatty alcohol sulfates, fatty alcohol ether sulfates, alkylol-amide sulfates and sulfonates, fatty acid alkyolamide polyglycol ether sulfates, alkanesulfonates and hydroxyafkanesulfonates, olefinsulfonates, acyl esters of isothionates, a-sulfofatty acid esters, alkylbenzosulfonates, alkylphenol glycol ether sulfonates, sulfosuccinates, sulfosuccinic acid hemiesters and diesters, fatty alcohol ether phosphates, protein-fatty acid condensation products, alkylmonoglyceride sulfates and sulfonates, alkylglyceride ether sulfonates, fatty acid methyltaurides, fatty acid sarcosinates or sulforicinoleates. These compounds and their mixtures are used in the form of their water-soluble or water-dispersible salts, for example the sodium, potassium, magnesium, ammonium, mono-, di- and triethanolammonium as well as analogous alkylolammonium salts.
Examples of amphoteric surfactants which can be added to the shampoos are: N-((C~ 2-C1 g)-alkyl)-~i-aminopropionates and N-((C12-C1 g)-alkyl)-~3-iminodipropionates as alkali metal and mono-) di- and trialkylol-ammonium salts; N-acylamidoalkyl-N,N-dimethylacetobetaine, preferably N-((Cg-C~ g)-acyl)amidopropyl-N,N-dimethylacetobetaine; (C12-C1 g)-alkyl-dimethylsulfopropylbetaine; amphoteric surfactants based on imidazoline
7 (trade name: Miranol~, Steinapon~), preferably the sodium salt of 1-((3-carboxymethyloxyethyl)-1-(carboxymethyl)-2-laurylimidazolinium;
amine oxides, e.g. (Ct2-Cog)-alkyldimethylamine oxide or fatty acid amidoalkyldimethylamine oxide.
Suitable nonionic surfactants which can be employed as detergent sub-stances are, for example: fatty alcohol ethoxylates (alkyl polyethylene glycols); alkylphenol polyethylene glycols; alkylmercaptan polyethylene glycols; fatty amine ethoxylates (alkylamino polyethylene glycols); fatty acid ethoxylates (acyl polyethylene glycols)) polypropylene glycol ethoxylates (Pluronic~); fatty acid alkylolamides (fatty acid amide polyethylene glycols);
sucrose esters; alkyl polyglucosides; sorbitol esters and polyglycol ether.
Suitable cationic surfactants are, for example, quaternary ammonium salts such as di-((C~ p-C24)-alkyl)dimethylammonium chloride or bromide, preferably di-((C~ 2-C~ g)-alkyl)dimethylammonium choride or bromide;
(Cep-C24)-alkyldimethylethylammonium chloride or bromide; (C1p-C24)-alkyltrimethylammonium chloride or bromide, preferably cetyltrimethyl-ammonium chloride or bromide and (C2p-C22)-alkyltrimethylammonium chloride or bromide; (Cep-C24)-alkyldimethylbenzylammonium chloride or bromide; preferably (C~ 2-C1 g)-alkyldimethylbenzylammonium chloride;
N-((C~ p-C~ g)-alkyl)pyridinium chloride or bromide, preferably N-((C12-C~ 6)-alkyl)pyridinium chloride or bromide; N-((C1 p-C1 g)-alkyl)isoquinolinium chloride, bromide or monoalkylsulfate; N-((Ct 2-C~ g)-alkylcolaminoformyl-methyl)pyridinium chloride; N-((C~ 2-C~ g)-alkyl)-N-methylmorpholinium chloride, bromide or monoalkylsulfate, N-((C~ 2-C~ $)-alkyl)-N-ethyl-morpholinium chloride, bromide or monoalkylsulfate; (C~ g-C~ g)-alkyl-pentaoxethylammonium chloride; diisobutylphenoxyethoxyethyldimethyl-benzylammonium chloride; salts of N,N-diethylaminoethylstearylamide and -oleylamide with hydrochloric acid, acetic acid, lactic acid, citric acid, phosphoric acid; N-acyfamidoethyl-N,N-diethyl-N-methylammonium chloride, bromide or monoalkylsulfate and N-acylamidoethyl-N,N-diethyl-N-benzylammonium chloride, bromide or monoalkylsulfate, where aryl is preferably stearyl or oleyl.
The preparations according to the invention can additionally contain further additives, e.g. aromatic substances, colorants, opacifiers and pearl luster agents, for example esters of fatty acids and polyols, magnesium and zinc salts of fatty acids, dispersions based on copolymers, thickeners such as sodium, potassium or ammonium chloride, sodium sulfate, fatty acid alkylolamides, cellulose derivatives of natural gums, collagen hydrolyzates, furthermore fats, oils, fatty alcohols, silicones, substances having a kerato-lytic and keratoplastic action, for example sulfur, salicylic acid or enzymes.
The shampoos are prepared in a manner known per se by mixing together of the individual components and a further processing - if necessary -suited to the particular type of preparation. Some of these various possible preparations are described by way of example in the working examples.
The preparations according to the invention can also be present in the form of aqueous and aqueous-alcoholic hair lotions, and also those in gel form and in aerosol form as spray or foam. Alcohols employed are preferably ethanol and isopropyl alcohol.
Further preparations which may be mentioned in which the 1-hydroxy-2-pyridones can be used according to the invention are, for example, cream and ointment preparations, products which are primarily used for the treatment of hairless head and body parts.
The preparation of all these preparations is also carried out - as already mentioned in the case of shampoo - in a manner known per se with addition of the active compound employed according to the invention. Of the abovementioned 1-hydroxy-2-pyridones, the preparations according to the invention can contain one compound or even several in combination.
The pH of the preparations is in the skin-physiological range of approximately pH 4.5 to 6.5. Whereas, when using the compounds in salt form, the adjustment of the pH range mentioned has to be carried out using organic acids, this measure is not necessary when using the free compounds.
In the preparations according to the invention, the active compounds is incorporated in amounts which are customarily between approximately 0.05 and approximately 10%. W ithin this range, the concentrations of the specific preparations depend on their intended use. Certain preparation forms such as concentrates, which are to be diluted before use, can have considerably higher concentrations.
If they are preparations which remain on the skin and on the scalp, for example gel preparations, ointments, creams or hair lotions, lower concen-trations will be employed, for example from about 0.05% to about 1 %, preferably from 0.1 to 0.5%. In higher concentrations, they will expediently be used when they are preparations which, optionally after dilution, only act on the scalp for a short time, for example shampoos or liquid soaps. In these cases, for example, concentrations of approximately 0.2 to approxi-mately 10%, preferably from approximately 0.5% to approximately 2%, can be expedient.
The following quantitative data relate to the weight, if not stated otherwise.
Example 1 A preparation according to the invention has the following composition:
Shampoo (based on anionic detergent substances) 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)pyridone 1.00%
Sodium lauryl diglycol ether sulfate (27% strength solution) 40.00%
Disodium lauryl polyglycol ether sulfosuccinate (33% strength solution) 10.00%
Sodium chloride 2.50%
Water 46.50%
Example 2 A preparation according to the invention has the following composition:
Shampoo 5 (based on anionic detergent substance with amphoteric surfactant as cosurfactant) 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)pyridone 1.00%
Sodium lauryl diglycol ether sulfate (27% strength36.00%
solution) Cocamidopropylbetaine (30% strength solution) 6.00%
Sodium chloride __ 3.30%
Water 53.70%
10 Example 3 A preparation according to the invention has the following composition:
Shampoo (based on anionic detergent substance with nonionic surfactant as cosurfactant) 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)pyridone 1.50%
Sodium lauryl diglycol ether sulfate (27% strength solution) 30.00%
Lauryl alcohol polyglucoside 8.00%
Sodium chloride 2.00%
Water 58.50%
Example 4 A preparation according to the invention has the following composition:
Liquid soap 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)pyridone 1.00%
Sodium lauryl diglycol ether sulfate (27% strength35.00%
solution) Cocamidopolyglycol ether sulfate magnesium salt (30% strength solution) 8.00%
Cocamidopropylbetaine (30% strength solution) 10.00%
Lauryl alcohol glycol ether _ 2.00%
Sodium chloride 2.00%
Water 42.00%
Example 5 A preparation according to the invention has the following composition:
Hair lotion 1-Hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxymethyl]-2(1 H)pyridone 0.05%
2-Propanol 60.00%
Water 39.95%
Example 6 A preparation according to the invention has the following composition:
Gel preparation 1-Hydroxy-4-methylcyclohexyl-2(1 H)pyridone0.75%
2-Propanol 15.0Q%
2-Octyldodecanol 7.50%
Carbomer 4,000,000 0.50%
Polysorbate 60 1.50%
Sodium hydroxide 0.18%
Water 74.57%
Example 7 A preparation according to the invention has the following composition:
Cream preparation 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)-pyridone, aminoethanol salt 1:1 1.00%
2-Octyldodecanol 7.50%
Liquid paraffin 7.50%
Stearyl alcohol 7.50%
Cetyl alcohol 7.50%
Polysorbate 60 3.00%
Sorbitan monostearate 2.00%
Lactic acid, 90% strength 0.51 Water 63.49%
Example 8 In a clinical study with a total of 180 patients, it was possible to show that the symptoms of seborrheic dermatitis of the scalp (severe scaling, inflam-mation, itching) can be effectively treated by a 1-2 x weekly treatment with a 1 % strength ciclopirox shampoo preparation over a period of 4 weeks.
Example 9 __ In a clinical study, it was possible to successfully treat 180 patients with seborrheic dermatitis of the scalp, of the face and of the upper body by application of a 0.77% strength ciclopirox gel preparation over a period of 4 weeks.
amine oxides, e.g. (Ct2-Cog)-alkyldimethylamine oxide or fatty acid amidoalkyldimethylamine oxide.
Suitable nonionic surfactants which can be employed as detergent sub-stances are, for example: fatty alcohol ethoxylates (alkyl polyethylene glycols); alkylphenol polyethylene glycols; alkylmercaptan polyethylene glycols; fatty amine ethoxylates (alkylamino polyethylene glycols); fatty acid ethoxylates (acyl polyethylene glycols)) polypropylene glycol ethoxylates (Pluronic~); fatty acid alkylolamides (fatty acid amide polyethylene glycols);
sucrose esters; alkyl polyglucosides; sorbitol esters and polyglycol ether.
Suitable cationic surfactants are, for example, quaternary ammonium salts such as di-((C~ p-C24)-alkyl)dimethylammonium chloride or bromide, preferably di-((C~ 2-C~ g)-alkyl)dimethylammonium choride or bromide;
(Cep-C24)-alkyldimethylethylammonium chloride or bromide; (C1p-C24)-alkyltrimethylammonium chloride or bromide, preferably cetyltrimethyl-ammonium chloride or bromide and (C2p-C22)-alkyltrimethylammonium chloride or bromide; (Cep-C24)-alkyldimethylbenzylammonium chloride or bromide; preferably (C~ 2-C1 g)-alkyldimethylbenzylammonium chloride;
N-((C~ p-C~ g)-alkyl)pyridinium chloride or bromide, preferably N-((C12-C~ 6)-alkyl)pyridinium chloride or bromide; N-((C1 p-C1 g)-alkyl)isoquinolinium chloride, bromide or monoalkylsulfate; N-((Ct 2-C~ g)-alkylcolaminoformyl-methyl)pyridinium chloride; N-((C~ 2-C~ g)-alkyl)-N-methylmorpholinium chloride, bromide or monoalkylsulfate, N-((C~ 2-C~ $)-alkyl)-N-ethyl-morpholinium chloride, bromide or monoalkylsulfate; (C~ g-C~ g)-alkyl-pentaoxethylammonium chloride; diisobutylphenoxyethoxyethyldimethyl-benzylammonium chloride; salts of N,N-diethylaminoethylstearylamide and -oleylamide with hydrochloric acid, acetic acid, lactic acid, citric acid, phosphoric acid; N-acyfamidoethyl-N,N-diethyl-N-methylammonium chloride, bromide or monoalkylsulfate and N-acylamidoethyl-N,N-diethyl-N-benzylammonium chloride, bromide or monoalkylsulfate, where aryl is preferably stearyl or oleyl.
The preparations according to the invention can additionally contain further additives, e.g. aromatic substances, colorants, opacifiers and pearl luster agents, for example esters of fatty acids and polyols, magnesium and zinc salts of fatty acids, dispersions based on copolymers, thickeners such as sodium, potassium or ammonium chloride, sodium sulfate, fatty acid alkylolamides, cellulose derivatives of natural gums, collagen hydrolyzates, furthermore fats, oils, fatty alcohols, silicones, substances having a kerato-lytic and keratoplastic action, for example sulfur, salicylic acid or enzymes.
The shampoos are prepared in a manner known per se by mixing together of the individual components and a further processing - if necessary -suited to the particular type of preparation. Some of these various possible preparations are described by way of example in the working examples.
The preparations according to the invention can also be present in the form of aqueous and aqueous-alcoholic hair lotions, and also those in gel form and in aerosol form as spray or foam. Alcohols employed are preferably ethanol and isopropyl alcohol.
Further preparations which may be mentioned in which the 1-hydroxy-2-pyridones can be used according to the invention are, for example, cream and ointment preparations, products which are primarily used for the treatment of hairless head and body parts.
The preparation of all these preparations is also carried out - as already mentioned in the case of shampoo - in a manner known per se with addition of the active compound employed according to the invention. Of the abovementioned 1-hydroxy-2-pyridones, the preparations according to the invention can contain one compound or even several in combination.
The pH of the preparations is in the skin-physiological range of approximately pH 4.5 to 6.5. Whereas, when using the compounds in salt form, the adjustment of the pH range mentioned has to be carried out using organic acids, this measure is not necessary when using the free compounds.
In the preparations according to the invention, the active compounds is incorporated in amounts which are customarily between approximately 0.05 and approximately 10%. W ithin this range, the concentrations of the specific preparations depend on their intended use. Certain preparation forms such as concentrates, which are to be diluted before use, can have considerably higher concentrations.
If they are preparations which remain on the skin and on the scalp, for example gel preparations, ointments, creams or hair lotions, lower concen-trations will be employed, for example from about 0.05% to about 1 %, preferably from 0.1 to 0.5%. In higher concentrations, they will expediently be used when they are preparations which, optionally after dilution, only act on the scalp for a short time, for example shampoos or liquid soaps. In these cases, for example, concentrations of approximately 0.2 to approxi-mately 10%, preferably from approximately 0.5% to approximately 2%, can be expedient.
The following quantitative data relate to the weight, if not stated otherwise.
Example 1 A preparation according to the invention has the following composition:
Shampoo (based on anionic detergent substances) 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)pyridone 1.00%
Sodium lauryl diglycol ether sulfate (27% strength solution) 40.00%
Disodium lauryl polyglycol ether sulfosuccinate (33% strength solution) 10.00%
Sodium chloride 2.50%
Water 46.50%
Example 2 A preparation according to the invention has the following composition:
Shampoo 5 (based on anionic detergent substance with amphoteric surfactant as cosurfactant) 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)pyridone 1.00%
Sodium lauryl diglycol ether sulfate (27% strength36.00%
solution) Cocamidopropylbetaine (30% strength solution) 6.00%
Sodium chloride __ 3.30%
Water 53.70%
10 Example 3 A preparation according to the invention has the following composition:
Shampoo (based on anionic detergent substance with nonionic surfactant as cosurfactant) 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)pyridone 1.50%
Sodium lauryl diglycol ether sulfate (27% strength solution) 30.00%
Lauryl alcohol polyglucoside 8.00%
Sodium chloride 2.00%
Water 58.50%
Example 4 A preparation according to the invention has the following composition:
Liquid soap 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)pyridone 1.00%
Sodium lauryl diglycol ether sulfate (27% strength35.00%
solution) Cocamidopolyglycol ether sulfate magnesium salt (30% strength solution) 8.00%
Cocamidopropylbetaine (30% strength solution) 10.00%
Lauryl alcohol glycol ether _ 2.00%
Sodium chloride 2.00%
Water 42.00%
Example 5 A preparation according to the invention has the following composition:
Hair lotion 1-Hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxymethyl]-2(1 H)pyridone 0.05%
2-Propanol 60.00%
Water 39.95%
Example 6 A preparation according to the invention has the following composition:
Gel preparation 1-Hydroxy-4-methylcyclohexyl-2(1 H)pyridone0.75%
2-Propanol 15.0Q%
2-Octyldodecanol 7.50%
Carbomer 4,000,000 0.50%
Polysorbate 60 1.50%
Sodium hydroxide 0.18%
Water 74.57%
Example 7 A preparation according to the invention has the following composition:
Cream preparation 1-Hydroxy-4-methyl-6-cyclohexyl-2(1 H)-pyridone, aminoethanol salt 1:1 1.00%
2-Octyldodecanol 7.50%
Liquid paraffin 7.50%
Stearyl alcohol 7.50%
Cetyl alcohol 7.50%
Polysorbate 60 3.00%
Sorbitan monostearate 2.00%
Lactic acid, 90% strength 0.51 Water 63.49%
Example 8 In a clinical study with a total of 180 patients, it was possible to show that the symptoms of seborrheic dermatitis of the scalp (severe scaling, inflam-mation, itching) can be effectively treated by a 1-2 x weekly treatment with a 1 % strength ciclopirox shampoo preparation over a period of 4 weeks.
Example 9 __ In a clinical study, it was possible to successfully treat 180 patients with seborrheic dermatitis of the scalp, of the face and of the upper body by application of a 0.77% strength ciclopirox gel preparation over a period of 4 weeks.
Claims (9)
1. The use of 1-hydroxy-2-pyridone of the formula I
in which R1, R2 and R3, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and R4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
where X is S or O, Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine, Z is a single bond or the bivalent radicals O, S, -CR 2 -, in which R is H or (C1-C4)-alkyl), or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a chain, where - if the radicals contain 2 or more oxygen and/or sulfur atoms - the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C1-C4)-alkyl groups, Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy, (C1-C4)-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form, for the production of a medicated shampoo, comprising at least one anionic, cationic, nonionic or amphoteric surfactant or a mixture of the surfactants and which has a pH in the skin-physiological range for the treatment of seborrheic dermatitis.
in which R1, R2 and R3, which are identical or different, are a hydrogen atom or alkyl having 1-4 carbon atoms, and R4 is a saturated hydrocarbon radical having 6 to 9 carbon atoms or a radical of the formula II
where X is S or O, Y is a hydrogen atom or up to 2 halogen atoms such as chlorine and/or bromine, Z is a single bond or the bivalent radicals O, S, -CR 2 -, in which R is H or (C1-C4)-alkyl), or other bivalent radicals having 2-10 carbon and, if appropriate, oxygen and/or sulfur atoms linked in the form of a chain, where - if the radicals contain 2 or more oxygen and/or sulfur atoms - the latter must be separated from one another by at least 2 carbon atoms and where 2 adjacent carbon atoms can also be linked to one another by a double bond and the free valences of the carbon atoms are saturated by H and/or (C1-C4)-alkyl groups, Ar is an aromatic ring system having up to two rings which can be substituted by up to three radicals from the group consisting of fluorine, chlorine, bromine, methoxy, (C1-C4)-alkyl, trifluoromethyl and trifluoromethoxy, in free or in salt form, for the production of a medicated shampoo, comprising at least one anionic, cationic, nonionic or amphoteric surfactant or a mixture of the surfactants and which has a pH in the skin-physiological range for the treatment of seborrheic dermatitis.
2. The use as claimed in claim 1, wherein the compound of the formula I is employed in which Ar is a bicyclic system which is derived from biphenyl, diphenylalkane or diphenyl ether.
3. The use as claimed in claim 1 or 2, wherein the compound of the formula I contains a cyclohexyl radical in the position R4.
4. The use as claimed in one or more of claims 1 to 3, wherein the compound of the formula I contains an octyl radical of the formula -CH2-CH(CH3)-CH2-C(CH3)3 in the position R4.
5. The use as claimed in claim 1, wherein 1-hydroxy-4-methyl-6-[4-(4-chlorophenoxy)phenoxymethyl]-2(1H)pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2(1H)pyridone or 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2(1H)pyridone is employed.
6. The use as claimed in claim 1, wherein the surfactant employed is at least one anionic surfactant on its own or as a mixture with other anionic surfactants and/or amphoteric surfactants.
7. The use as claimed in claim 1, wherein the 1-hydroxy-2-pyridone of the formula I is employed in a concentration of 0.2% to 10 [lacuna].
8. The use as claimed in claim 7, wherein the 1-hydroxy-2-pyridone of the formula I is employed in a concentration of 0.5% to 2%.
9. The use as claimed in claim 1, wherein the medicated shampoo has a pH of approximately 4.5 to 6.5.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19639818A DE19639818A1 (en) | 1996-09-27 | 1996-09-27 | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
DE19639818.5 | 1996-09-27 | ||
PCT/EP1997/005070 WO1998013009A2 (en) | 1996-09-27 | 1997-09-16 | Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2267165A1 CA2267165A1 (en) | 1998-04-02 |
CA2267165C true CA2267165C (en) | 2003-12-16 |
Family
ID=7807118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002267165A Expired - Lifetime CA2267165C (en) | 1996-09-27 | 1997-09-16 | Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis |
Country Status (32)
Country | Link |
---|---|
EP (1) | EP0928183B1 (en) |
JP (2) | JP2001500884A (en) |
KR (1) | KR100494207B1 (en) |
CN (1) | CN1104231C (en) |
AR (1) | AR008860A1 (en) |
AT (1) | ATE209891T1 (en) |
AU (1) | AU716208B2 (en) |
BG (1) | BG64365B1 (en) |
BR (1) | BR9711575A (en) |
CA (1) | CA2267165C (en) |
CY (1) | CY2362B1 (en) |
CZ (1) | CZ291485B6 (en) |
DE (2) | DE19639818A1 (en) |
DK (1) | DK0928183T3 (en) |
ES (1) | ES2167721T3 (en) |
HK (1) | HK1022267A1 (en) |
HU (1) | HU226955B1 (en) |
ID (1) | ID21874A (en) |
IL (1) | IL129141A0 (en) |
MA (1) | MA24333A1 (en) |
MY (1) | MY125674A (en) |
NO (1) | NO312492B1 (en) |
NZ (1) | NZ334850A (en) |
OA (1) | OA11028A (en) |
PL (1) | PL188033B1 (en) |
PT (1) | PT928183E (en) |
RS (1) | RS49801B (en) |
TR (1) | TR199900662T2 (en) |
TW (1) | TW519491B (en) |
UA (1) | UA57754C2 (en) |
WO (1) | WO1998013009A2 (en) |
ZA (1) | ZA978640B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19639816A1 (en) | 1996-09-27 | 1998-04-02 | Hoechst Ag | Antifungal agents with high drug release |
US20040039030A1 (en) | 1996-09-27 | 2004-02-26 | Hoechst Akeengesellschaft | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis |
US20050095215A1 (en) * | 2003-11-03 | 2005-05-05 | Popp Karl F. | Antimicrobial shampoo compositions |
ES2402041T3 (en) | 2007-08-31 | 2013-04-26 | Janssen Pharmaceutica, N.V. | Combinations of imazalil and hydroxypyridones |
CN101877968A (en) | 2007-11-30 | 2010-11-03 | 詹森药业有限公司 | Fungicidal azole compounds and pyrion combination of compounds |
CN101932243B (en) | 2008-02-06 | 2014-04-23 | 詹森药业有限公司 | Combinations of phenylpyrroles and pyrion compounds |
EP2587920B1 (en) | 2010-07-01 | 2016-08-10 | Janssen Pharmaceutica, N.V. | Antimicrobial combinations of pyrion compounds with polyethyleneimines |
ES2573116T3 (en) * | 2010-12-02 | 2016-06-06 | The University Of Kansas | Prodrugs of 6-cyclohexyl-1-hydroxy-4-methylpyridin-2 (1H) -one and its derivatives |
WO2013011996A1 (en) * | 2011-07-19 | 2013-01-24 | リジェンティス株式会社 | Polyphosphoric acid composition containing polyphosphoric acid extracted from yeast cell, salt of polyphosphoric acid or solvate of polyphosphoric acid, and method for producing same |
FR2983858B1 (en) * | 2011-12-08 | 2014-01-03 | Fabre Pierre Dermo Cosmetique | NOVEL INHIBITORY COMPOUNDS OF LIPOGENESIS |
CN104744359B (en) * | 2015-03-06 | 2017-10-10 | 上药康丽(常州)药业有限公司 | A kind of process for purification of Ciclopirox |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2234009C3 (en) * | 1972-07-11 | 1979-01-11 | Hoechst Ag, 6000 Frankfurt | Cosmetic preparations |
NL8601762A (en) * | 1986-07-07 | 1988-02-01 | Bouke Jan Lange | METHOD FOR CLEANING AND CONDITIONING AND ANY MEDICINAL TREATMENT OF HAIR AND SCALP, A TWO-PHASE SHAMPOO USABLE FOR THIS PURPOSE AND PACKAGING FOR IT. |
CA2143329A1 (en) * | 1992-09-08 | 1994-03-17 | Karen K. Kalla | Mild, substantially colorless shampoo composition |
DE4333893A1 (en) * | 1993-10-05 | 1995-04-06 | Hoechst Ag | Cosmetic preparations |
FR2722689B1 (en) * | 1994-07-20 | 1996-10-04 | Fabre Pierre Dermo Cosmetique | NOVEL COMBINATION PRODUCT COMPRISING AN ANTIFUNGAL AGENT AND CROTAMITON AS A POTENTIALIZER OF THE ACTIVITY OF THE ANTIFUNGAL AGENT, AND DERMATOLOGICAL AND / OR COSMETIC COMPOSITIONS COMPRISING THE SAME |
-
1996
- 1996-09-27 DE DE19639818A patent/DE19639818A1/en not_active Withdrawn
-
1997
- 1997-09-16 AT AT97910294T patent/ATE209891T1/en active
- 1997-09-16 AU AU47746/97A patent/AU716208B2/en not_active Expired
- 1997-09-16 CA CA002267165A patent/CA2267165C/en not_active Expired - Lifetime
- 1997-09-16 CZ CZ19991075A patent/CZ291485B6/en not_active IP Right Cessation
- 1997-09-16 PL PL33260397A patent/PL188033B1/en unknown
- 1997-09-16 HU HU9903811A patent/HU226955B1/en unknown
- 1997-09-16 RS YUP-134/99A patent/RS49801B/en unknown
- 1997-09-16 ID IDW990129A patent/ID21874A/en unknown
- 1997-09-16 WO PCT/EP1997/005070 patent/WO1998013009A2/en active IP Right Grant
- 1997-09-16 IL IL12914197A patent/IL129141A0/en not_active IP Right Cessation
- 1997-09-16 BR BR9711575A patent/BR9711575A/en not_active Application Discontinuation
- 1997-09-16 PT PT97910294T patent/PT928183E/en unknown
- 1997-09-16 EP EP97910294A patent/EP0928183B1/en not_active Expired - Lifetime
- 1997-09-16 KR KR10-1999-7002553A patent/KR100494207B1/en not_active IP Right Cessation
- 1997-09-16 DK DK97910294T patent/DK0928183T3/en active
- 1997-09-16 JP JP10515223A patent/JP2001500884A/en active Pending
- 1997-09-16 CN CN97198266A patent/CN1104231C/en not_active Expired - Lifetime
- 1997-09-16 TR TR1999/00662T patent/TR199900662T2/en unknown
- 1997-09-16 NZ NZ334850A patent/NZ334850A/en not_active IP Right Cessation
- 1997-09-16 DE DE59705697T patent/DE59705697D1/en not_active Expired - Lifetime
- 1997-09-16 ES ES97910294T patent/ES2167721T3/en not_active Expired - Lifetime
- 1997-09-16 UA UA99042351A patent/UA57754C2/en unknown
- 1997-09-25 TW TW086113944A patent/TW519491B/en not_active IP Right Cessation
- 1997-09-25 AR ARP970104432A patent/AR008860A1/en not_active Application Discontinuation
- 1997-09-26 MY MYPI97004501A patent/MY125674A/en unknown
- 1997-09-26 ZA ZA9708640A patent/ZA978640B/en unknown
- 1997-09-29 MA MA24814A patent/MA24333A1/en unknown
-
1999
- 1999-03-17 BG BG103260A patent/BG64365B1/en unknown
- 1999-03-25 NO NO19991460A patent/NO312492B1/en not_active IP Right Cessation
- 1999-03-26 OA OA9900071A patent/OA11028A/en unknown
-
2000
- 2000-02-28 HK HK00101194A patent/HK1022267A1/en not_active IP Right Cessation
-
2003
- 2003-05-26 CY CY0300044A patent/CY2362B1/en unknown
-
2006
- 2006-03-22 JP JP2006078057A patent/JP2006176540A/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2689991B2 (en) | Composition | |
JP2006176540A (en) | Medicated shampoo for treating seborrheic dermatitis | |
JPS6220167B2 (en) | ||
US8227490B2 (en) | Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis | |
EP0884997B1 (en) | Compositions containing an antifungal and a sulfur compound | |
JP2020525428A (en) | Topical composition | |
KR100564386B1 (en) | A pharmaceutical composition for the treatment of seborrhea containing 4-hydroxy-5-methoxy-4-[2-methyl-3-3-methyl-2-butenyl-2-oxiranyl]-1-oxaspiro[2,5]octan-6-one | |
JPH07187968A (en) | Make-up goods preparation | |
EP3723714B1 (en) | Propanediol monoacetate mononitrate | |
EP0276151B1 (en) | Dissolved composition of [benzo-1,2,4-thiadiazine]-1,1-dioxide for hair germination and hair growth promotion. | |
JPS6040403B2 (en) | Anti-dandruff cleansers or lotions | |
MXPA99002864A (en) | Use of 1-hydroxy-2-pyridone for the treatment of seborrheic dermatitis | |
JPH04364107A (en) | Hair tonic | |
JPH04364108A (en) | Hair tonic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20170918 |